French polymer manufacturer contributing bioplastic processing and biomedical material expertise to EU research consortia.
SOFRADIM PRODUCTION SASU is a French private manufacturing company based in Trevoux with expertise in polymer-based materials and biomaterial processing. Their industrial capabilities span biomedical applications — specifically tissue engineering components for medical repair — and advanced packaging materials such as polyhydroxyalkanoate (PHA) bioplastics. In EU research consortia, they serve as an industrial manufacturing partner, providing scale-up and processing expertise that translates lab-scale materials into manufacturable products. Their dual presence in medical device research and sustainable packaging suggests a core polymer processing competency applied across sectors.
Both H2020 projects involve polymer-based materials — biomedical microenvironments in Tendon Therapy Train and PHA-based plastics in NENU2PHAR — pointing to a core industrial competency in processing advanced polymers.
NENU2PHAR (2020–2024) focuses on polyhydroxyalkanoate materials for high-volume consumer products including food packaging and bioplastic recycling.
Tendon Therapy Train (2016–2020) involved engineering in vitro microenvironments for cell-based therapies targeting tendon repair, suggesting familiarity with medical-grade biomaterial requirements.
In the earlier period (2016–2020), SOFRADIM's EU project involvement was rooted in biomedical research — specifically cell-based therapies and tissue engineering for tendon repair — consistent with a medical device manufacturing background. By 2020–2024, their focus shifted clearly toward sustainable materials: polyhydroxyalkanoates, bioplastic processing, food packaging, and circular economy applications. This transition likely reflects the company applying existing polymer manufacturing know-how to the fast-growing bioplastics market rather than abandoning medical expertise.
SOFRADIM is repositioning polymer processing capabilities toward sustainable packaging and PHA bioplastics, suggesting deliberate entry into high-growth green materials markets alongside their established medical materials work.
SOFRADIM participates exclusively as a consortium member — they have not led any H2020 project. Despite only two projects, they engaged with 32 unique partners across 12 countries, indicating participation in large, multi-partner consortia rather than small bilateral collaborations. This pattern suggests they join research networks as an industrial end-user or manufacturing partner, providing real-world processing context to academically led projects.
32 unique partners across 12 countries from just two projects, indicating consistent involvement in large European research consortia. No geographic concentration is evident from the available data.
SOFRADIM bridges industrial polymer manufacturing and research-grade biomaterials — a combination that few private companies bring to EU consortia. Their dual experience in medical device materials and sustainable bioplastics makes them an attractive industrial partner for any project that needs to validate material processing at production scale. As a non-SME French manufacturer, they also bring production infrastructure and commercial credibility that smaller research partners cannot offer.
